CureVac Shareholders Face Critical Decision Point in BioNTech Takeover

Investors in CureVac are approaching a pivotal moment as the acquisition by BioNTech enters its final stages. With a crucial deadline looming, shareholders must determine their position regarding the proposed share exchange. This comes as BioNTenhances transparency through recently released financial data, leaving market participants to evaluate whether the swap remains advantageous or if the opportunity has already passed.

The acquiring company has strengthened its takeover proposition by publishing an updated prospectus containing current financial metrics. These disclosures aim to provide clarity around the proposed all-stock transaction, which would allow CureVac shareholders to exchange their holdings for newly issued American Depositary Shares (ADSs) of BioNTech.

Key financial details relevant to the acquisition evaluation include:

Should investors sell immediately? Or is it worth buying CureVac?

• BioNTech reported revenue of €1.96 billion for the initial three quarters of 2025
• The company maintains its full-year outlook despite recording a net loss
• Revenue projections for 2025 remain steady at €2.6 to €2.8 billion

Shareholder Decision Window Narrows

The takeover process has intensified as the acceptance period for CureVac investors rapidly concludes. This deadline forces shareholders to make definitive decisions regarding their investment positions. Market observers are closely monitoring how investors will respond during these critical final days of the offer period.

CureVac's stock performance has become almost exclusively tied to the acquisition dynamics rather than the company's operational developments. The share price trajectory now hinges entirely on shareholder decisions regarding the exchange offer and the successful completion of BioNTech's acquisition strategy.